Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, fatal neurodegenerative disease characterised by the death of upper and lower motor neurons. Approximately 10% of cases have a known family history of ALS and disease-linked mutations in multiple genes have been identified. ALS-linked mutations in CCNF were recently reported, however the pathogenic mechanisms associated with these mutations are yet to be established. To investigate possible disease mechanisms, we developed in vitro and in vivo models based on an ALS-linked missense mutation in CCNF. Proteomic analysis of the in vitro models identified the disruption of several cellular pathways in the mutant model, including caspase-3 mediated cell death. Transient overexpression of human CCNF in zebrafish embryos supported this finding, with fish expressing the mutant protein found to have increased levels of cleaved (activated) caspase-3 and increased cell death in the spinal cord. The mutant CCNF fish also developed a motor neuron axonopathy consisting of shortened primary motor axons and increased frequency of aberrant axonal branching. Importantly, we demonstrated a significant correlation between the severity of the CCNFinduced axonopathy and a reduced motor response to a light stimulus (photomotor response). This is the first report of an ALS-linked CCNF mutation in vivo and taken together with the in vitro model identifies the disruption of cell death pathways as a significant consequence of this mutation. Additionally, this study presents a valuable new tool for use in ongoing studies investigating the pathobiology of ALS-linked CCNF mutations.
Introduction
Amyotrophic lateral sclerosis (ALS) is typically a late onset neurodegenerative disease, characterised by rapidly progressive loss of motor neurons in the motor cortex, brainstem and spinal cord. The majority of patients die from the disease within 3-5 years of diagnosis (1) . In addition to progressive motor dysfunction, approximately 50% of ALS patients develop some degree of cognitive impairment and an estimated 15% are diagnosed with concurrent frontotemporal dementia (ALS-FTD) (2) . ALS and FTD are clinically, pathologically and genetically linked, suggesting that they are two ends of a spectrum of neurodegenerative diseases rather than distinct pathologies (2) . The pathogenesis of these diseases remains poorly understood and effective treatments are desperately required.
Approximately 10% of ALS patients have a known family history of the disease. To date, gene mutations are the only proven cause of ALS (reviewed most recently in (3)), however the aetiology of the disease is complex, with significant clinical heterogeneity and a variable penetrance of ALS-linked mutations. No single genetic model of ALS is capable of reflecting all pathological aspects of the disease, therefore studies investigating disease pathophysiology must rely on multiple models directed to known molecular pathways of interest. Over the past decade, zebrafish have emerged as a valuable tool both for investigations into the cellular and molecular mechanisms of neurodegenerative diseases and also for preliminary screening of potential therapeutics (4) .
Our laboratory recently identified ALS and FTD-linked mutations in CCNF, which account for 0.6 to 3.3% of familial ALS cases (5) . Cyclin F, encoded by CCNF, mediates the ubiquitination and consequently degradation of target proteins through the ubiquitin proteasome system (6) . In vitro expression of mutant CCNF has been shown to alter ubiquitination of target proteins and result in increased intracellular accumulation of ubiquitinated proteins, suggesting that aberrant protein homeostasis plays a role in the pathogenesis of CCNF mutations (5) .
In this study, we developed both in vitro and in vivo models to assess key cellular mechanisms involved in the pathobiology of a disease-linked CCNF mutation. The models were based on a serine to glycine mutation (p.S621G) that demonstrates segregation with disease in a family with both ALS and FTD sufferers (5) . We identified cell death as a critical cellular pathway affected by mutant CCNF, demonstrated a significant motor axonopathy associated with overexpression of mutant CCNF in vivo and demonstrated that this motor axon impairment can be linked to an aberrant motor phenotype in the zebrafish.
Results
Proteomic analysis of in vitro models identified multiple cellular pathways disrupted by mutant CCNF Neuro-2a cells were transfected with wild type CCNF cDNA (CCNF WT ), CCNF cDNA with the p.S621G mutation (CCNF S621G ) or an empty vector control (Fig. 1 ). Cells were harvested at 8-and 24-h post-transfection and proteomic analysis performed on the lysates to identify proteins differentially expressed between the CCNF S621G and CCNF WT transfected cells.
At 8 and 24 h, 200 and 187 proteins were up-regulated, respectively, with 42 (12.2%) common proteins identified between the two timepoints. In contrast, at 8 and 24 h, 261 and 207 proteins were down-regulated respectively, with 48 (11.4%) of the identified proteins common between the two timepoints.
The complete dataset of this analysis is available via ProteomeXchange with identifier "PXD005131" (www.proteo mexchange.org; date last accessed April 13, 2017) .
Gene Ontology (GO) analysis was used to examine the biological functions of these differentially up-and down-regulated proteins. This analysis demonstrated that although the overlap of differentially expressed proteins between the two timepoints was relatively modest, the proteins cluster to specific functional classifications and these classifications are similar at both timepoints. This suggests that the expression of mutant cyclin F affects specific biological processes, most particularly, catalytic and binding activity (Figs 2 and 3) . At both timepoints, over 90% of the binding proteins identified as differentially expressed were specifically involved in nucleic acid and protein binding, while over 60% of the catalytic proteins were involved in hydrolase and transferase activity (Supplementary Materials, Figs S2-5).
To gain further insight into the biological functions and processes altered by CCNF S621G expression, we employed Ingenuity Pathway Analysis (IPA, Quiagen). IPA clusters the proteins identified as being differentially expressed, allowing a prediction of the resultant activation/inhibition status of entire networks, canonical pathways and biological processes. This analysis predicted the cellular death pathway as being significantly activated at both 8 h (Z-Score: 2.84, P-value ¼ 7.98e-87) and 24 h (Z-Score: 2.24, P-value ¼ 1.06e-8) (Fig. 4) . Interestingly, this included a prediction of increased activity of caspase 3, believed to be a key mediator of cell death in ALS (7) . Supporting this prediction, caspase 3 was identified by the proteomic analysis as being up-regulated 1.7 fold at 24 h (P-value ¼ 0.058), a result validated by western blot analysis (Fig. 5 ). These proteomic findings prompted the development of CCNF expressing zebrafish in order to explore disruption to these cellular functions in vivo.
Characterisation of endogenous ccnf in the zebrafish
To investigate the suitability of the zebrafish to model CCNF mutations, we first confirmed that endogenous ccnf is expressed in the central nervous system of the fish. In situ hybridisation (ISH) and RT-PCR showed ccnf RNA expression in the zebrafish nervous system throughout development to maturity (Fig. 6 ). Whole mount ISH was performed from the 6-somite stage of development through to 5 days post-fertilisation (dpf) (Fig. 6A ). Ubiquitous expression of ccnf was recognised at 12-h post-fertilisation (hpf), with the strongest expression in the central nervous system at 48 hpf. ISH demonstrated ccnf RNA was strongly expressed in the brain up to 5 dpf. Ongoing expression in whole brain tissue was confirmed beyond 5 dpf into adulthood by RT-PCR (Fig. 6B) .
Homology comparison of zebrafish and human cyclin F confirmed that the same functional domains are present in both species and that these domains are located at similar positions in the respective proteins and that the p.S621G mutation in the human gene is orthologous to p.S623G in the zebrafish. However, the zebrafish ccnf gene shares only 61.4% nucleotide sequence identity with the human gene (Fig. 7) . Given this substantial difference in nucleotide sequences, the human orthologue was used to generate the CCNF-based models to maximise the model's ability to reflect changes associated with the ALS-linked mutation. 
Generation of cyclin F-expressing zebrafish
Human CCNF WT and CCNF S621G mRNA was injected into zebrafish embryos at the single cell stage and equal expression of the respective proteins were confirmed by western blot of lysates collected at 8 hpf (Fig. 8 ). Zebrafish were staged matched by somite number and the overall length of the fish was measured at 24 hpf and 3 dpf to identify any subtle developmental delay associated with cyclin F overexpression. This analysis demonstrated no significant differences between uninjected control embryos (CTR) and embryos injected with either CCNF Overexpression of cyclin F S621G in vivo led to abnormal axonal outgrowth
To assess the influence of overexpression of cyclin F on axon development, we measured the length of the ventral projections of the primary motor neuron axons (ventral root) and assessed the branching of this ventral root in CCNF mRNA-injected zebrafish ( Overexpression of cyclin F S621G in vivo led to reduced motor function
Motor function of the zebrafish was assessed through the photomotor response (PMR), which uses light stimuli to induce a brief excitation phase (11) . Fish were classified as being responsive or non-responsive to the light stimulus (Fig. 11A ). Per clutch, on average 25.2% 62.4 of the CCNF S621G injected group failed to respond to the stimuli, which was significantly greater than both the CCNF WT group (6.7% 62.1, P 0.0001) and the CTR group (8.4% 60.9, P 0.001) (Fig. 11A ). No significant difference was observed in the number of fish that failed to respond between the CCNF WT and the CTR groups.
For those fish that did respond to the stimuli, the distance swum was measured (Fig. 11B) 11B) . A significant difference in swim distance was also detected between the CCNF WT and the CTR groups (P 0.05).
To confirm that the abnormal axonal morphology associated with CCNF S621G expression was relevant to this altered behavioural response, we examined the relationship between length of the ventral root and the swimming distance for each fish as well as the severity of aberrant branching and swimming distance for each fish (Fig. 12) . Correlation analysis revealed a statistically significant relationship between locomotor function and ventral root length (Spearman's correlation coefficient, rho (q) ¼ 0.45, P 0.0001), as well as locomotor function and severity of aberrant branching (q ¼ À0.30, P 0.001) (Fig. 12) . Taken together, our findings strongly suggest that the ALS-linked CCNF p.S621G mutation causes a significant axonopathy leading to reduced motor function in the zebrafish.
Discussion
ALS-and FTD-linked gene mutations were recently identified in CCNF in widespread populations (5) . Here we present the first in vivo assessment of mutant CCNF. CCNF expressing zebrafish were used to validate our proteomic findings which indicated that disruption to cell death pathways, including up-regulation of caspase 3, occur as a consequence of expression of the mutant protein. Characterisation of the CCNF-expressing zebrafish suggests that the mutant protein also induces aberrant axonal outgrowth. This data suggests a toxic gain-of-function mechanism of action of the CCNF S621G mutation and specifically, that disruption of the cell death pathway and impaired axonal outgrowth are key features in the pathobiology of CCNF-linked ALS. However, further studies in which cyclin F expression is reduced will be required to establish whether a loss-of-function mechanism also contributes to mutant CCNF pathogenesis. Further studies are also required to examine the effect of mutant CCNF on protein ubiquitination. Previously published in vitro data indicates that expression of mutant cyclin F results in increased intracellular accumulation of ubiquitinated proteins (5), however we did not observe a similar increase in out mutant CCNF zebrafish (Supplementary Material, Fig. S12 ). We hypothesise that this due to the relatively brief period of expression of the mutant protein in these transient models. Stably expressing transgenic models will be required to establish whether this pathology develops over time.
The axonopathy that was induced by the transient overexpression of mutant CCNF in the zebrafish was shown to correlate with impaired motor function. While a number of established zebrafish models of ALS already show that axonopathies are a common phenotype (10) (11) (12) (13) (14) (15) (16) , this is the first time that a causal relationship between altered axonal outgrowth and reduced motor function has been demonstrated in a zebrafish model of ALS. We observed no developmental delay in the mutant zebrafish, and skeletal muscle morphology was also unaffected, indicating that the motor phenotype observed was not a consequence of an overall developmental defect, rather a mutation-specific effect. Evidence indicates that the role of disrupted axonal outgrowth in neurodegenerative diseases extends beyond embryonic axonal development. For example, modified expression of the axonal guidance protein EPHA4 has been shown to rescue the phenotype of two separate zebrafish models of ALS (SOD1 G93A and TARDBP
A315T
) and to increase survival in both mouse and rat SOD1 G93A models (17) . It is hypothesised that proteins involved in this pathway play a role in the synaptic plasticity of neurons in the adult nervous system and that dysregulation may underlie denervation of the neuromuscular junctions, one of the earliest pathological changes in ALS (reviewed in (18)). To differentiate between the effect of mutant CCNF during development and its effect in differentiated cells, it will be useful to develop an inducible model that allows temporal control of cyclin F expression. Further studies into the pathways through which mutant CCNF up-regulates the cell death pathways would also be of interest. In combination, our in vitro and in vivo analysis provides strong evidence that disruption to these pathways is a consequence of mutant CCNF expression, however the cell death pathways involved in ALS are currently poorly understood. Motor neuron death in ALS is often attributed to apoptosis, but there remains doubt over whether the apoptotic cascade is solely responsible (19) . ALS patient tissue demonstrates some, but not all of the characteristic pathology of apoptosis (20) , and the pathological changes seen in the SOD1 G93A mouse model have led some to hypothesise that paraptosis -a nonapoptotic form of programmed cell death is involved (21) . More recently, necroptosis, a form of programmed necrosis has been proposed as the mechanism of cell death in ALS (22) . Regardless of the specific pathway involved, capsase-3 is believed to be a key mediator of cell death in multiple neurodegenerative diseases including ALS, Alzheimer's disease, Parkinson's disease and Huntington's disease (reviewed in (7)). Established evidence for a role of caspase-3 in ALS includes elevated levels of caspase-3 activity in both patient tissue (19) and in the SOD1 G93A mouse model (23), suggesting up-regulation of the protein in disease and its potential as a therapeutic target. The findings presented in this study appear to support this evidence. The cleaved caspase 3 immunostaining and the acridine orange staining were performed in separate fish to examine the level of cell death. Now work can commence to specify which specific cell death pathway is activated by expression of mutant CCNF.
To date, the CCNF protein, cyclin F, has only five characterised substrates -RRM2, CP110, NuSAP, CDC6, and SLBP (6), none of which were identified as being differentially expressed in our proteomic analysis. The analysis did identify over 400 proteins that were differentially expressed in CCNF S621G transfected ells compared to CCNF WT transfected cells at both 8 and 24 h, indicating that the p,S621G mutation does have significant downstream effects on multiple pathways. Unravelling these interactions and consequences will provide significant insight in to the pathological mechanisms of this mutation. The evidence presented here suggests that the in vitro and in vivo overexpression models may prove to be useful tools in these investigations. Additionally, the cellular and behavioural phenotypes displayed by the mutant CCNF zebrafish offer a robust readout for preclinical trials of potential therapeutics.
Materials and Methods

Plasmid generation
The Q5 Site-Directed Mutagenesis kit mutagenesis kit (NEB) was used to introduce a point mutation (c. 1861A > G) into CCNF within the mCherry-CCNF plasmid (a gift from Michele Pagano, Addgene plasmid # 32975) (24) . This produced an amino acid change from serine to glycine at amino acid 621. For generation of mRNA, mCherry-fused CCNF WT and CCNF S621G was subcloned into the pCS2þ vector using the EcoR1
and Xhol restriction enzyme sites with primers 5'-CAGTGA ATTCGAATGGTGAGCAAGGGCGAGGAG and 5'-TCGACTCGAGG ATCAGAAGCTCAGAAAGG.
Transfection of CCNF into neuro-2a cells
The murine Neuro-2a cell line was grown and maintained in Dulbecco's Modified Eagle Medium (DMEM; Sigma Aldrich) supplemented with 10% fetal bovine serum (Sigma Aldrich), 100 mg/mL streptomycin (Sigma Aldrich), and 100 U/mL penicillin (Sigma Aldrich) in a 37 C incubator with 5% CO 2 and 95%
humidity. Transfection of CCNF WT and CCNF S621G plasmids were performed using Lipofectamine 2000 (Life Technologies) and opti-MEM media (Life Technologies). Expression of mCherry fused cyclin F was confirmed through western blotting using lysates collected at 8, 24 and 48-h post-transfection (Fig. 1) . CCNF transfected Neuro-2a cells were harvested in ice-cold phosphate buffered saline (PBS) at 80% confluence, pelleted by centrifugation, and stored at À80 C if not used immediately.
Cell pellets were resuspended in sodium deoxycholate lysis buffer (1% sodium deoxycholate, 0.1 M triethylammonium bicarbonate, 1.5 mM magnesium chloride, pH 8.0) and incubated at 95 C for 2 min. Lysates were then cooled and 1 ll benzonase nuclease (Novagen) was added to digest genomic DNA, followed by probe sonication (10 pulses, Setting 3, Branson Sonifier). Cellular debris was pelleted by centrifugation at 14,000 g for 30 min at 4 C.
Western blotting
Protein concentration was determined using the Pierce TM BCA Protein Assay Kit and the Western blotting performed as previously described (25) . Briefly, lysates were electrophoresed into 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was blocked with 3% BSA for 1 h at room temperature, followed by1 h incubation at room temperature in antibody solution. Cyclin F rabbit polyclonal 1:500 (Santa Cruz), Caspase 3 rabbit polyclonal 1:1000 (Cell Signalling Technology), HDAC2 mouse monoclonal 1:1000 (abcam), PSBM2 rabbit polyclonal 1:1000 (Bethyl laboratories Inc.), TDP-43 rabbit polyclonal 1:1000 (Proteintech), GAPDH rabbit polyclonal 1:5000 (SigmaAldrich) and b-actin mouse monoclonal 1:2000 (Sigma-Aldrich) primary antibodies were used followed by the appropriate antirabbit (Promega) or anti-mouse (Sigma-Aldrich) secondary antibodies (1:5000). Blots were developed with a chemiluminescent substrate (BioRad, Clarity Western ECL Substrate) and imaged with ImageQuant LAS4000 (GE Healthcare Life Sciences).
Trypsin digestion
Approximately 100 mg of protein was reduced with 10 mM dithiothreitol for 30 min at 55 C and alkylated with 55 mM iodoacetamide for 1 h at room temperature in the dark. Trypsin (1 mg) was added and incubated overnight at 37 C. Following trypsin digestion, formic acid (1 ml) was added to kill residual trypsin activity and acidify the sample to precipitate the sodium deoxycholate. The peptide sample was recovered by centrifugation at 14,000 g for 30 min, desalted on a C 18 SepPak cartridge (Waters), and vacuum centrifuged to dry peptides. Peptides were stored at À80 C until LC-MS/MS analysis.
Mass spectrometry and cellular pathway analysis of cell lysates
A label-free quantitative mass spectrometry workflow was used to identify changes in protein expression associated with cyclin F WT and cyclin F S621G at 8-and 24-h post-transfection.
Lyophilised peptides were resuspended in 0.1% (v/v) formic acid and analysed using on-line C 18 reverse phase nanoscale liquid chromatography tandem mass spectrometry. 20 lg of sample was injected using an Eksigent nano-LC system with cHiPLCV R system coupled to the 5600 TripleTOF TM mass spectrometer (AB SCIEX) equipped with a nanoelectrospray ionisation emitter (PicoTip Emitter, New Objective). The 5600 Triple TOF TM was operated in an informationdependant acquisition (IDA) mode involving 1 full MS scan between 350-1500 m/z, and 20 MS/MS scans generating approximately 15-20 points per peak. Chosen parameters were monoisotopic precursor selection, charge state screening and dynamic exclusion. Charge states that were unassigned, >4 or þ1 were not selected for MS/MS fragmentation. The raw files (*.wiff) from each analysis was searched in the ProteinPilot software incorporating the Mascot search algorithm using Swissprot_2014_04 database (selected for Mus musculus; 16676 entries). The following search parameters were chosen: carbamidomethylation of cysteines as a fixed modification, and methionine oxidation and protein amino-terminal acetylation as variable modifications. Enzyme specificity was set to trypsin and allowed for 2 missed cleavages. Parent ion tolerance was set at 50 ppm and MS/MS fragment ion tolerance was within 0.1 Da. Peptide charges were set to 2þ, 3þ and 4þ. A targetdecoy search strategy using a reversed database to estimate protein false discovery rates, which was set to 1% false discovery rate (FDR).
We employed label-free quantitative proteomics employing normalised spectral abundance factors (NSAF), which takes into account the length of a given protein as well as the total amount of protein in a given sample. A fraction (0.5) of a spectral count was added to all samples to account for missing values and total spectral counts for at least one condition was equal to 6 . NSAF values were log2-transformed and Student's t-tests were used to identify significant (P 0.05) changes in protein abundance between CCNF WT and CCNF S621G transfected cells. Statistical data preparation and tests were done using Microsoft Excel. Enriched GO annotations and signalling pathways were identified using the Database for Annotation, Visualization and Integrated Discovery (DAVID) and IngenuityV R Pathway Analysis (IPA; QIAGEN). The mass spectrometry proteomics data has been deposited to the ProteomeXchange Consortium via the PRIDE (26) partner repository with the dataset identifier PXD005131 (Username: reviewer51075@ebi.ac.uk; Password: i6pPz1LY).
Alignment of human and zebrafish CCNF
Human and zebrafish CCNF cDNA (NM_001761 and NM_207048 respectively) and amino acid sequences (NP_001752.2 and NP_996931.1) were compared using Clustal Omega 2.0 (http:// www.ebi.ac.uk/Tools/msa/clustalo/; date last accessed April 13, 2017).
RT-PCR amplification of zebrafish ccnf cDNA
For analysis in the developing zebrafish, whole embryos were collected for RNA extraction at 1-5 dpf. For analysis throughout the growth phase to maturity, total RNA was extracted from zebrafish brain at 1, 2 and 3 months post-fertilisation.
Total RNA was extracted from 50 whole embryos or from 2 brains per age group using the RNeasy RNA extraction kit (Qiagen). The Tetro Reverse Transcriptase kit (Bioline) was used to generate zebrafish cDNA from 5 mg extracted RNA. A 450 bp fragment of ccnf was PCR amplified from the cDNA using internal ccnf primers spanning a 2.7 kb intron (5'-AGACCGTGAGGGC GAGGGAGA and 5'-TCGAGAATTCGATCAGAAGCTCAGAAAGG). actb1 primers were used as a positive control (27) and primers designed to amplify human CCNF cDNA as a negative control (5'-GCTAGCGAATGGGGAGCGGCGGCGTGGT and 5'-CTTAAGGA TTACAGCCTCACAAGGCCCA). RT-PCR amplification was performed using an Eppendorf Mastercycler with standard MyTaq (Bioline) PCR cycling conditions and an annealing temperature of 58 C.
In situ hybridisation (ISH)
Zebrafish ccnf was PCR amplified from pCMV_SPORT_ccnf (Millennium science) with Phusion polymerase (NEB) using primers designed to add a 5' T3 promoter sequence (5'-CATTAA CCCTCACTAAAGGGAACTGTAAGCTGACTTTCCCTG) and a 3' T7 promoter sequence (5'-TAATAACGACTCATAGGAAACACTACAG CCTTGCAGC). Following purification (ISOLATE II PCR and Gel Kit, Bioline), in vitro transcription was performed with T3 or T7 RNA polymerases and digoxygenin (DIG) labelling mix (Roche) to produce sense and antisense riboprobes. Whole-mount ISH was performed as previously described (28) with minor modifications including pre-hybridisation, hybridisation and post-hybridisation washes at 60 C and blocking with FBS for 2 h at 4 C prior to the addition of DIG antibody.
After staining, embryos were rinsed in phosphate buffered saline with 0.1% (v/v) Tween 20 and fixed in 4% (w/v) paraformaldehyde. Embryos were mounted in 3% methylcellulose and imaged using a Leica M165FC stereo dissection microscope.
Zebrafish lines
Zebrafish used in this study were either non-transgenic AB/ Tü bingen wild type (TAB_WT) or transgenic fish that expressed blue fluorescent protein in their motor neurons on a TAB_WT background Tg(-3mnx1:TagBFP)mq 10 (29) . Fish were bred and maintained under established conditions (30) and all husbandry and experimental procedures were performed in compliance with the Animal Ethics Committee, Macquarie University (NSW, Australia) and the Animal Ethics Committee, University of Sydney (NSW, Australia). Only morphologically normal embryos were used for analysis and all embryos were stage matched through somite counts at 24 hpf. Only zebrafish that were within 61-2 somite stages of development were used in the analysis.
Generation of mRNA and injection into zebrafish embryos pCS2þ mCherry-CCNF WT and -CCNF S621G were linearised by Not1 restriction enzyme digest (NEB), purified using QIAquick Gel Extraction Kit (Qiagen) and mRNA generated by in vitro transcription using a mMESSAGE mMACHINE SP6 transcription kit (Thermo Fisher Scientific). A dose-response curve was performed (50-200 ng), which established 150 ng as the maximum dose which resulted in less than 10% of embryos developing gross abnormalities by 24 hpf. The mRNA was injected at the one-cell stage of development using a Picospritzer II (Parker Instrumentation) under a Nikon SMZ 745 stereomicroscope. Embryos were screened for mCherry expression in the animal pole at approximately 6 hpf under a M165FC fluorescent stereomicroscope (Leica).
Collection of protein lysates from zebrafish
Embryos were manually dechorinated at 8 hpf, euthanised in 50 mg/L tricaine (MS222) and rinsed in PBS before being deyolked using deyolking buffer (55 mm NaCl, 1.8 mm KCl, 1.25 mm NaHCO 3 ) and homogenised in RIPA buffer (20 mm TrisHCl, pH 7.4, 1% Triton X-100, 150 mm NaCl, complete protease inhibitor cocktail, Roche Applied Sciences). Western blotting was performed as previously described.
Birefringence analysis of skeletal muscle morphology
Birefringence analysis was performed as previously described (8) . Zebrafish embryos were euthanised at 3 dpf, mounted on a glass slide and imaged on a M165FC fluorescent stereomicroscope (Leica) fitted with polarised lenses located above and below the embryo. The lenses were oriented at 90 to each other and images taken at 3.2 x magnification with the same exposure time and gain. The mean intensity of each embryo was quantified using ImageJ (n ¼ 30 per group). Values for the CCNF WT and CCNF S621G injected groups were normalised to the uninjected group.
Acridine orange staining
Zebrafish embryos were euthanised at 24 hpf and placed in 5 lg/ml acridine orange (Sigma Aldrich) for 10 min. Embryos were rinsed, then mounted in 3% methylcellulose and imaged on a M165FC fluorescent stereomicroscope (Leica) scope. The number of acridine orange positive cells in the spinal cord of the first five upper somites immediately caudal to the yolk ball/ tube boundary was manually counted for each embryo (n ¼ 30 per group).
Caspase-3 staining
Zebrafish embryos were euthanised at 20 hpf and incubated for 10 min at 28 C in 2 mg/ml Pronase (Sigma-Aldrich), to 
In vivo analysis of axonal branching
Zebrafish embryos were manually dechorinated at 30 hpf and fixed in 4% PFA. Immunostaining was performed with mouse anti-SV2 primary antibody (1:200), a marker of motor neuron axons (Developmental Studies Hybridoma Bank) and Alexa Fluor 488 anti-mouse secondary antibody 1:300 (Molecular Probes). Embryos were mounted in 3% methylcellulose and imaged on a M165FC fluorescent stereomicroscope (Leica). The first five ventral axonal projections of the primary motor neurons immediately caudal to the yolk ball/tube boundary were assessed. If two or more axons branched at or above the ventral edge of the notochord, the embryo was scored as aberrant (10) .
In vivo analysis of axonal length
Zebrafish embryos were manually dechorinated at 32 hpf, euthanised at 48 hpf and fixed in 4% PFA. Embryos were mounted in 3% methylcellulose and imaged on a M165FC fluorescent stereomicroscope (Leica). Images were analysed using the ImageJ plug-in NeuronJ. For each embryo, the first 10 venral root projections immediately caudal to the yolk ball/tube boundary were measured from the cell body to the distal tip of the axon and the average taken for each embryo (10).
Photomotor response (PMR)
Behavioral analysis was performed using the Zebrabox (Viewpoint) following the manufacturer's instructions for the PMR (11) . Embryos were manually dechorinated at 32 hpf, raised in equal numbers (n ¼ 30 per petri dish) at 28 C until 42 hpf in the dark. Embryos were then individually placed in a 96-well plate filled with E3 embryo medium, allowed to recover then moved into the Zebrabox. Ten minutes was allowed for acclimatisation, then a 1 second, 300 watt light stimulus was used to elicit the PMR, which was tracked using Zebralab software (View-point). This stimulus was repeated twice at one-min intervals. Analysis was performed of both the percentage of embryos that responded to the light and the distance swum by each fish (mm). Embryos that failed to move were discarded from analysis of average distance swum.
Correlation between axonal length/aberrant branching and swimming behaviour
The Tg(-3mnx1:TagBFP)mq 10 transgenic line was used for this analysis. The PMR was performed at 42 hpf as previously described and embryos incubated at 28 C until 48 hpf. At this point they were euthanised and the morphology of the motor neurons assessed. Motor neuron length was determined for each embryo as previously described. A qualitative assessment of aberrant branching at 48hpf was performed according to an established method (31) . Briefly, the first 10 primary motor neuron axons immediately caudal to the yolk ball/tube boundary were scored bewteen 1 and 4. Neurons were classified as normal (score ¼ 1), mildly aberrant (score ¼ 2), moderately aberrant with excessive branching or innervation of the neighbouring myotome, but no truncation (score ¼ 3) or severely aberrant with truncation (score ¼ 4).
Statistical analysis of in vivo data
All statistical analysis was performed on three independent experiments in biological triplicates. Statistical analysis of cell death, caspase-3 staining, embryo length, birefringence, motor neuron length and motor function, was performed with an ordinary one-way ANOVA and the Tukey's HSD post hoc test to determine significant differences at a 95% confidence interval.
The relationships between motor neuron length and motor function, and motor neuron score and motor function was found to be non-linear, so correlation analysis was assessed with Spearman's correlation coefficient, rho (q) with a twotailed P-value and a confidence interval of 95%.
All values in the figures are shown as means 6 standard error of the mean (SEM) (*P 0.05; **P 0.01, ***P 0.001, ****P 0.0001).
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